All In Biotech

Drug Trial Radar · NCT07397949

Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery

A Randomized Noninferiority Trial Comparing Rebamipide and Diquafosol for Perioperative Dry Eye Management in Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to compare two commonly used eye drop treatments for dry eye disease in patients undergoing cataract surgery. Dry eye disease is common in people who need cataract surgery and may worsen before or after surgery, causing eye discomfort, blurred vision, and unstable vision. Proper management of dry eye before and after surgery may help improve eye comfort and the accuracy of vision outcomes. In this study, patients with mild to moderate dry eye disease who are scheduled for cataract surgery will be randomly assigned to receive one of two treatments: Rebamipide eye drops, or Diquafosol eye drops Participants will begin using the assigned eye drops one month before cataract surgery and continue treatment for three months after surgery. The eye drops will be used only in the eye undergoing surgery. Researchers will examine whether one treatment is as effective as the other in improving tear film stability and reducing dry eye symptoms around the time of cataract surgery. Eye examinations and questionnaires will be performed before surgery, on the day of surgery, and during follow-up visits after surgery. The information gained from this study may help doctors choose the most appropriate treatment for managing dry eye disease in patients undergoing cataract surgery.

Conditions

  • Dry Eye Disease (DED)
  • Cataract

Interventions

  • Rebamipide 2% ophthalmic solutionDrug

    Topical administration to the surgical eye, four times daily.

  • Diquafosol 3% ophthalmic solutionDrug

    Topical administration to the surgical eye, four times daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Tear Film Breakup Time (TBUT)Time frame: From baseline to postoperative 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Mec

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.